Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble
adverse drug reactions
Research
Lipid may hold the key to new liver drugs
New research may finally offer a way to confer the benefits of SCD1 inhibitors without the associated serious side effects.
James Waldron
Jun 7, 2022 6:00am
Aligos calls it quits on 2nd med after 'unexpected' reactions
Mar 22, 2022 10:40am
Redx cleared to start Wnt cancer trial again after safety scare
Jan 21, 2019 9:05am
Redx pauses WNT cancer trial following adverse events
Mar 29, 2018 3:35am
Seattle Genetics stops all trials of '33A blood cancer drug
Jun 19, 2017 9:37am
Patient death raises doubts about safety of Roche’s emicizumab
Feb 24, 2017 4:37am
